dalteparin has been researched along with Diabetes Mellitus in 8 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin." | 9.12 | Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. ( Apelqvist, J; Blombäck, M; Eliasson, B; Eriksson, JW; Fagrell, B; Hamsten, A; Jörneskog, G; Kalani, M; Silveira, A; Torffvit, O, 2007) |
| " We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin." | 5.12 | Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. ( Apelqvist, J; Blombäck, M; Eliasson, B; Eriksson, JW; Fagrell, B; Hamsten, A; Jörneskog, G; Kalani, M; Silveira, A; Torffvit, O, 2007) |
| "Diabetes mellitus is a major contributor to CAD." | 2.71 | Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. ( Diderholm, E; Lagerqvist, B; Lindahl, B; Malmberg, K; Norhammar, A; Rydén, L; Wallentin, L, 2004) |
| "Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug has to alter the effects of another when both are administered simultaneously." | 1.56 | Potential drug-drug interactions in ICU patients: a retrospective study. ( Ali, I; Bazzar, A; Hussein, N; Sahhar, E, 2020) |
| " The aim of this prospective study was to determine the lowest single bolus dose of low-molecular-weight heparin nadroparin for safe and effective HD in patients with a bleeding risk." | 1.37 | The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis. ( Jelicic, I; Kovacic, V; Ljutic, D; Radic, J; Sain, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sain, M | 1 |
| Ljutic, D | 1 |
| Kovacic, V | 1 |
| Radic, J | 1 |
| Jelicic, I | 1 |
| Ali, I | 1 |
| Bazzar, A | 1 |
| Hussein, N | 1 |
| Sahhar, E | 1 |
| Ilhan, O | 1 |
| Ilhan, N | 1 |
| Coşkun, M | 1 |
| Dağlioğlu, MC | 1 |
| Ayhan Tuzcu, E | 1 |
| Ayintap, E | 1 |
| Keskın, U | 1 |
| Oksüz, H | 1 |
| Roffi, M | 2 |
| Eberli, FR | 1 |
| Carballo, S | 1 |
| Carballo, D | 1 |
| Keller, PF | 1 |
| Skeppholm, M | 1 |
| Kallner, A | 1 |
| Kalani, M | 2 |
| Jörneskog, G | 2 |
| Blombäck, M | 2 |
| Wallén, HN | 1 |
| Norhammar, A | 1 |
| Malmberg, K | 1 |
| Diderholm, E | 1 |
| Lagerqvist, B | 1 |
| Lindahl, B | 1 |
| Rydén, L | 1 |
| Wallentin, L | 1 |
| Silveira, A | 1 |
| Apelqvist, J | 1 |
| Eliasson, B | 1 |
| Eriksson, JW | 1 |
| Fagrell, B | 1 |
| Torffvit, O | 1 |
| Hamsten, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence of the Appearance of Diabetic Ulcers, After the Manufacture and Adaptation of Personalized Insoles, With Monitoring of Temperature and Plantar Pressure in Diabetic Patients[NCT05843929] | 86 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Diabetes Mellitus
| Article | Year |
|---|---|
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
3 trials available for dalteparin and Diabetes Mellitus
| Article | Year |
|---|---|
The effect of enoxaparin-containing irrigation fluid used during cataract surgery on postoperative inflammation in patients with diabetes.
Topics: Aged; Anterior Chamber; Anticoagulants; Cataract; Cataract Extraction; Diabetes Mellitus; Diabetic R | 2013 |
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
Topics: Aged; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dalteparin; Diabetes Co | 2004 |
Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers.
Topics: Aged; Dalteparin; Diabetes Mellitus; Double-Blind Method; Female; Fibrinolytic Agents; Foot Ulcer; H | 2007 |
4 other studies available for dalteparin and Diabetes Mellitus
| Article | Year |
|---|---|
The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Diabetes Mellitus; Female; Hemorr | 2011 |
Potential drug-drug interactions in ICU patients: a retrospective study.
Topics: Aspirin; Diabetes Mellitus; Drug Interactions; Enoxaparin; Hospitalization; Humans; Hypertension; In | 2020 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogr | 2011 |
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Case-C | 2009 |